Évaluation comportementale et neuropsychologique d’une population d’enfants atteints de neurofibromatose de type 1 traites par méthylphenidate : une étude en plan croisé, randomisée en double insu du méthylphenidate versus placebo
Laurence Lion‐François(Centre National de la Recherche Scientifique), Behrouz Kassaï(Hospices Civils de Lyon), S. Pinson(Hôpital Edouard Herriot), Valentine Bréant(Lyon 1 Université), Tiphanie Ginhoux(Lyon 1 Université), Isabelle Kemlin(Sorbonne Université), Emeline Peyric(Sorbonne Université), Vania Herbillon(Centre de Recherche en Neurosciences de Lyon), P. Combemale(Centre Léon Bérard), Diana Rodriguez(Sorbonne Université), Daniel Gérard(Lyon 1 Université), François Gueyffier(Centre National de la Recherche Scientifique), Cédric Mercier(Inserm), Vincent Desportes(Hôpital Femme Mère Enfant), Vanessa Maruyama Martins Coutinho(Sorbonne Université)
Cited by 0
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188